Bone Therapeutics received notice that the European Patent Office (EPO) will grant the company a patent covering its allogeneic cell therapy technology.
Patents for the technology have been granted in Japan, Australia and Singapore and applications are pending in the U.S., Canada, India and South Korea.
In March, Bone Therapeutics completed recruitment of 16 patients in the Phase I/IIA delayed-union fracture study of its allogeneic cell therapy product, ALLOB®. Interim results are expected in 3Q17.
Bone Therapeutics received notice that the European Patent Office (EPO) will grant the company a patent covering its allogeneic cell therapy technology.
Patents for the technology have been granted in Japan, Australia and Singapore and applications are pending in the U.S., Canada, India and South Korea.
In March, Bone Therapeutics...
Bone Therapeutics received notice that the European Patent Office (EPO) will grant the company a patent covering its allogeneic cell therapy technology.
Patents for the technology have been granted in Japan, Australia and Singapore and applications are pending in the U.S., Canada, India and South Korea.
In March, Bone Therapeutics completed recruitment of 16 patients in the Phase I/IIA delayed-union fracture study of its allogeneic cell therapy product, ALLOB®. Interim results are expected in 3Q17.
Copy to clipboard 
